Showing results (11-20 of 372) with videos related to

Sort By:
Pageof 38
Blood|December 2, 2004
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Giovanni Palladini, Vittorio Perfetti, Stefano Perlini, et al.
The American Journal of Clinical Nutrition|February 14, 2006
Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1Riccardo Caccialanza, Giovanni Palladini, Catherine Klersy, et al.
Plos One|October 3, 2013
A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coliPaola Rognoni, Francesca Lavatelli, Simona Casarini, et al.
Blood Cancer Journal|September 3, 2020
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapyPaolo Milani, Marco Basset, Mario Nuvolone, et al.
Annals of Medicine|April 26, 2007
The workings of the amyloid diseasesVittorio Bellotti, Mario Nuvolone, Sofia Giorgetti, et al.
Haematologica|November 12, 2013
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approachGiovanni Palladini, Paolo Milani, Andrea Foli, et al.
Ageing Research Reviews|June 11, 2021
Age-related amyloidosis outside the brain: A state-of-the-art reviewMasayoshi Tasaki, Francesca Lavatelli, Laura Obici, et al.
American Journal of Hematology|March 6, 2012
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failureGiovanni Palladini, Andrea Foli, Paolo Milani, et al.
Annals of Hematology|May 3, 2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomideGiovanni Palladini, Paola Russo, Andrea Foli, et al.
Scientific Reports|December 3, 2017
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensityLuca Oberti, Paola Rognoni, Alberto Barbiroli, et al.
Pageof 38